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Abstract
Heterozygous germ-line mutations in the DNA mismatch repair genes
lead to hereditary nonpolyposis colorectal cancer. The disease suscepti-
bility of individuals who constitutionally lack both wild-type alleles is
unknown. We have identified three offspring in a hereditary nonpolyposis
colorectal cancer family who developed hematological malignancy at
a very early age, and at least two of them displayed signs of neurofibro-
matosis type 1 (NF1). DNA sequence analysis and allele-specific amplifi-
cation in two siblings revealed a homozygousMLH1 mutation
(C676T3Arg226Stop). Thus, a homozygous germ-lineMLH1 mutation
and consequent mismatch repair deficiency results in a mutator pheno-
type characterized by leukemia and/or lymphoma associated with neuro-
fibromatosis type 1.
Introduction
HNPCC4 is a common autosomal dominant disease characterized
by an inherited predisposition to early onset of colorectal cancer and
to an increased incidence of other cancers (1). Mutations inMLH1 and
MSH2are seen in.90% of HNPCC kindreds, whereas mutations in
PMS2,PMS1, andMSH6have been seen in only a few families (2).
HNPCC individuals are heterozygous for the mutant allele. Thus, they
retain a functional allele at the constitutional level, which is appar-
ently sufficient for DNA MMR (3). However, a subsequent somatic
mutation leading to loss of the wild-type allele results in a mutator
cancer phenotype characterized by a high rate of base substitutions, as
well as small insertions and deletions in mono- and dinucleotide
repeats (3). Somatic mutations in HNPCC tumors have been identified
in long mononucleotide tracts within the coding sequences of several
genes involved in the control of cell growth, includingTGFbRII,
IGFIIR, andBAX, as well as two additional MMR genes,MSH3and
MSH6 (Refs. 4–7). These downstream gene mutations have been
implicated in the progression of colorectal cancer. Thus, the result of
somatic loss of MMR gene function in individual cells has been well
characterized. However, the phenotypic consequence of a constitu-
tional loss of MMR gene function remains poorly understood. We
describe here a germ-line homozygous mutation of theMLH1 gene
that predisposes to NF1 and early childhood hematological malignan-
cies.
Materials and Methods
Patient Samples.Informed consent was obtained from all participants in
the study. Child IV-4 developed atypical chronic myeloid leukemia at 12
months, displayed more than 10 abdominal café au lait spots (.15 mm) and
two fibromatous skin tumors (2 cm), and showed hepatosplenic enlargement (8
cm). A differential blood count done at the time blood was drawn for DNA
analysis showed 28% polymorphonuclear cells, 9% lymphocytes, 48% mono-
cytes, 14% blasts, and 1% eosinophils. Bone marrow smear revealed 10%
promyelocytes, 8% myelocytes, 5% metamyelocytes, 22% polymorphonuclear
cells, 12% eosinophils, 18% normoblasts, and 25% blasts. Child IV-3 devel-
oped non-Hodgkin’s lymphoma at 39 months and displayed more than 10 café
au lait spots (.15 mm). Bone marrow smear revealed 33% normoblasts, 6%
promyelocytes, 12% myelocytes, 9% metamyelocytes, 6% polymorphnuclear
cells, and 34% lymphoblasts. Megakaryocytes were seen, and dysplasia was
not detected. Child IV-2 developed acute leukemia at 24 months; neurofibro-
matosis could not be confirmed.
DNA Sequence Analysis.Genomic DNA was isolated from peripheral
blood samples (except for child IV-3, for whom genomic DNA was isolated
from a bone marrow smear) by proteinase K lysis, phenol/chloroform extrac-
tion, and ethanol precipitation.MLH1 exon 8 primers, 59-CTCAGCCAT-
GAGACAATAAATCC-39 (forward) and 59-GGTTCCCAAATAATGT-
GATGG-39 (reverse), were used for both PCR amplification and cycle
sequencing. PCR amplification reactions were performed using GeneAmp
PCR Core Reagents (Perkin-Elmer, Foster City, CA). PCR parameters were
denaturation (95°C for 30 s), annealing (55°C for 30 s), and extension (72°C
for 60 s) for 30 cycles. Dye-terminator cycle sequencing reactions were
performed using the ABI PRISM Dye-Terminator Cycle Sequencing Ready
Reaction kit (Perkin-Elmer) according to the recommended protocol with the
following modifications. DMSO (5%) was included in the forward primer
reaction, and a denaturation temperature of 98°C was used for the reverse
primer. Automated fluorescence sequence analysis was performed on the 377
DNA Sequencer (ABI; Perkin-Elmer).
Allele-specific Amplification. Forward primers were designed for allele
specificity at the 39 terminal nucleotide: 59-GAAATGCTGTTAGTC-39(wild-
type) and 59-GAAATGCTGTTAGTT-39 (mutant). The reverse primer for both
alleles was 59-AGTGTTGATTACGTG-39. Amplification reactions contained
;25 ng of genomic DNA and 10 pmol of primer. PCR parameters were 35
cycles of denaturation (94°C for 30 s), annealing (50°C for 60 s), and extension
(72°C for 90 s). PCR products were analyzed by 3% Metaphor (FMC) gel
electrophoresis. The competition experiment was performed using a constant
amount of mutant DNA (50 ng) and dilutions (1:1, 2:1, 5:1, 50:1, and 500:1)
of wild-type DNA.
Results and Discussion
To identify individuals with a constitutional loss of MMR gene
function, we inspected large HNPCC kindreds for putative homozy-
gotes. TF3 is a large Turkish kindred that fulfills the Amsterdam
criteria (8) for HNPCC: colorectal cancer diagnosed at an early age
(26–58 years) in multiple first-degree relatives over three consecutive
generations (Fig. 1). Of particular genetic interest were three offspring
(IV-2, IV-3, and IV-4) of a consanguinous marriage. All three chil-
dren were diagnosed with hematological malignancy by the age of 3.
Received 9/16/98; accepted 11/25/98.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby markedadvertisementin accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported in part by a combined grant (Grant TTGV-172) from the
Technology Development Foundation of Turkey and Bilkent Holding. H. O¨ . received a
Bütünles(tirilmis( Doktora Program fellowship from the Scientific and Technical Research
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In addition, two of the children (IV-3 and IV-4) exhibited NF1. The
parents (III-5 and III-6), first-degree cousins, were both afflicted with
colon cancer at an early age. Two grandparents and one great-grand-
parent also developed colorectal cancer. Thus, the pedigree is con-
sistent with dominant inheritance of a colorectal cancer susceptibility
gene. However, the unexpected appearance of hematological malig-
nancy and NF1 in the offspring of the two heterozygous parents
suggested to us that the shift in disease phenotype from adult colo-
rectal cancers to juvenile hematological malignancy associated with
NF1 might be due to recessive inheritance of this same cancer sus-
ceptibility gene.
BecauseMLH1 mutations were identified previously in two Turk-
ish HNPCC families (9), we first analyzed this gene. Genetic testing
of the proband (III-4) by automated genomic DNA sequencing re-
vealed anMLH1 nonsense mutation (C676T3Arg226Stop). This
mutation has been described previously (10, 11) and results in a
severely truncated gene product expected to have no MMR function
(12). DNA sequence analysis of additional family members demon-
strated that the mutation cosegregated with colorectal cancer (Fig. 1).
Because both individuals in the consanguinous marriage (III-5 and
III-6) were heterozygous for the mutation (III-6 data shown in Fig.
2b), we next determined the genotypes of deceased offspring for
whom DNA was available. DNA sequence analysis performed on an
archival DNA sample from IV-4 and on DNA isolated from an
archival bone marrow smear from IV-3 revealed only the mutant
allele (IV-4 data shown in Fig. 2c).
Because the children’s DNA had been extracted from either pe-
ripheral blood or bone marrow, leukemic cells with loss of heterozy-
gosity might have masked the presence of a wild-type allele in normal
cells. DNA sequence analysis of independent PCR reactions demon-
strated only the mutant allele (data not shown). However, to rule out
preferential amplification of the mutant allele, we performed an allele-
specific amplification. As seen in Fig. 3, only the normal allele was
amplified from the control DNA sample; both alleles were amplified
from the parents’ DNA samples; and only the mutant allele was
amplified from both children’s DNA samples. Control experiments
demonstrated that the wild-type allele could be amplified in the
presence of 50-fold excess of mutant allele (data not shown). Al-
though confirmatory analysis of DNA from other tissues was not
possible, these results strongly suggest that both children were truly
homozygous for the mutant allele.
Two cases of constitutional loss ofMLH1 gene activity have been
described previously (13, 14). The first report describes a heterozy-
gous mutation (deletion of codon 618) associated with MMR defi-
ciency and microsatellite instability in normal cells, a phenotype that
the investigators proposed might be due to a dominant-negative effect
of this specific mutation (13). However, by age 31, this patient had
developed only two colorectal cancers, suggesting that the normal
cells may have retained some residual MMR activity not detected
under in vitro conditions. The second report describes an HNPCC
individual, diagnosed with breast cancer at age 35, who displayed
compound heterozygosity for twoMLH1 missense mutations (14).
Fig. 1. Pedigree of TF3. The generations are indicated with roman numerals (I–IV), and the individuals in each generation are specified with numbers ontopof the symbols.Squares,
male;circles, female;diamonds,individual whose sex is not specified (the number of individuals is given in each diamond); symbols with adiagonal,deceased individuals. Age of
diagnosis (affected individuals) or age (unaffected individuals) is indicated to the right,bottomof symbol.Solid symbol,HNPCC individual.Diagonal, shaded symbols,hematological
malignances.1, wild-type allele;2, mutantMLH1 allele.
Fig. 2. DNA sequence analysis. Portion of the electropherogram of the sense strand
sequencing of MLH exon 8.a, DNA sequence of a healthy individual;b, DNA sequence
of father (III-6); c, DNA sequence of child (IV-4).Arrow, heterozygous C3T MLH1
mutation.
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Although the investigators demonstrated microsatellite instability and
increasedin vitro mutation rate, one of the mutated gene products
likely retained residual MMR activity because it was lost in the tumor
cells. Thus, it is likely that this missense mutation was itself not
deleterious and that, therefore, this case does not represent constitu-
tional MLH1 deficiency. In contrast to these two studies, the mutation
that we have identified is a nonsense mutation that results in a
severely truncated, nonfunctional gene product. The children most
likely inherited the same allele from each parent and thus represent
true homozygotes. The resulting MLH1 deficiency appears to have
induced a severe tumorigenic syndrome, involving both hematological
malignancy and neurofibromatosis.
Our observations demonstrate that a homozygousMLH1 mutation
is not lethal but predisposes to juvenile hematological malignancy
associated with NF1, in contrast to HNPCC observed in heterozygous
individuals. NF1, an autosomal dominant disorder, with a predispo-
sition to neoplasms of neural crest origin and less frequently to
juvenile hematological malignancy, develops as a result ofNF1 gene
mutations (15, 16). The observation of both NF1 and hematological
malignancy inMLH1 homozygotes suggests that they also bear mu-
tations inNF1 and probably other genes. The clinical signs and the
inheritance mode of NF1 and hematological malignancy suggest that
the putative secondary mutations were not inherited but occurred as
early as the post-zygotic stage. Inheritance ofde novomutations from
heterozygous parents is possible (16) but unlikely because offspring
from the other apparentMLH1 heterozygotes displayed neither NF1
nor hematological malignancy (Fig. 1). Furthermore, these disorders
are not frequently associated with HNPCC (8). Thus, homozygous
MLH1 mutation in humans appears to create a mutator phenotype of
severe NF1 syndrome associated with juvenile hematological malig-
nancy. This contrasts with heterozygousMLH1 mutations that lead
mainly to colorectal cancers at a later age with a mean of 44 years (8).
These phenotypic differences provide important clues about MMR
gene-mediated carcinogenesis.
On the basis of evidence provided here and in other models
(17–20), we propose that tumorigenesis through an “MMR deficiency
pathway” requires at least three steps in normal individuals: (a)
heterozygous mutation creating a somatic “pro-mutator” phenotype;
(b) wild-type allele loss producing a somatic mutator phenotype; and
(c) downstream gene mutation(s) generating a cancer phenotype.
Tumors arising through this pathway would be extremely rare because
of the multiple steps required. In an individual with a constitutional
heterozygous MMR gene mutation, a “pro-mutator” phenotype would
lead to a mutator phenotype with loss of the wild-type allele in
preneoplastic cells, as observed in HNPCC (3). Clonal cells would
then become genetically unstable, resulting in downstream gene mu-
tations such asTGFbRII, IGFIIR, andBAX(4–6) that, in turn, lead to
loss of growth control. The rate-limiting step in this case would be
wild-type MMR gene loss preferentially occurring in colon epithelium
because of high cell turnover. In this pathway, colon cancers will arise
earlier and more frequently, as observed in HNPCC, because fewer
steps are required. A homozygous MMR gene mutation would create
a true mutator phenotype with constitutional genomic instability, as
described for mice (21), leading directly to downstream gene muta-
tions. The limiting factor in this case would be the susceptibility of
downstream gene(s) to MMR deficiency.NF1 and other genes in-
volved in hematopoiesis are good candidates as downstream genes.
Indeed, theNF1 mutation rate is about 10-fold higher than most other
genes (16). In this pathway, tumors would occur frequently and very
early in life. The tissue specificity of the cancers (and other disorders)
would be determined by the downstream genes affected, as illustrated
by our results and the data on MMR-deficient mice (21).
Our description of a homozygous germ-lineMLH1 mutation asso-
ciated with hematological malignancy and neurofibromatosis appears
not to be a unique and coincidental event. An independent study
describes two individuals with childhood malignancies (including
leukemia) and NF1 in a large HNPCC kindred from North Africa. At
least one of the children was shown to be homozygous for a germ-line
MLH1 mutation inherited from heterozygous parents (22). The strik-
ing similarity of these observations strengthens our interpretation of a
mutator phenotype of homozygous germ-line MMR gene mutations in
humans.
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